stockrow
Friday 6 November 2026
Export INSM’s income statement to Excel — free account
Insmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
112.58
3.82
+3.51%
Follow INSM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
16.43 | 20.37 | 42.99 | 57.12 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(684.93) | (260.89) | (158.18) | (139.89) | |
P/B ratio |
34.39 | 30.59 | 49.99 | 46.87 | |
Price to Tangible BV |
55.29 | 43.90 | 74.46 | 68.56 | |
EV/Sales |
16.20 | 20.04 | 42.46 | 56.05 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(41.32) | (29.27) | (38.85) | (36.35) | |
EV/FCF |
(39.22) | (28.23) | (37.75) | (35.13) | |
Quick Ratio |
2.36 | 3.14 | 3.88 | 3.35 | |
Current Ratio |
2.86 | 3.72 | 4.47 | 3.83 | |
Net Debt/EBITDA |
7.41 | (102.75) | 4.52 | 2.78 | |
Debt/Assets |
25.28% | 26.75% | 27.07% | 24.80% | |
Debt/Equity |
0.78 | 0.74 | 0.80 | 0.76 | |
Asset Turnover |
0.66 | 0.50 | 0.42 | 0.28 | |
Operating CF/Net income |
0.36 | 6.71 | 1.36 | 0.75 | |
Capex/Depreciation |
(0.53) | (0.85) | (0.49) | (2.18) | |
Interest Coverage |
(4.38) | (0.08) | (7.63) | (15.52) | |
Research and Development Expense of Revenue |
51.48% | 49.36% | 68.47% | 96.61% | |
Selling, General and Administrative Expense of Revenue |
48.25% | 58.16% | 80.81% | 80.53% | |
Intangible Assets out of Total Assets |
0.12 | 0.11 | 0.11 | 0.10 | |
Share Based Compensation of Revenue |
7.86% | 9.70% | 14.95% | 14.80% | |
Graham Net Nets |
0.01 | 0.01 | 0.01 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.47%) | (3.85%) | (3.52%) | (3.68%) | |
Free Cash Flow Yield |
(2.51%) | (3.49%) | (2.62%) | (2.79%) | |
Revenue per Share |
2.40 | 1.96 | 1.42 | 1.33 | |
Operating CF per Share |
(0.17) | (0.41) | (1.03) | (1.24) | |
Capex per Share |
(0.03) | (0.03) | (0.02) | (0.08) | |
Free Cash Flow per Share |
(0.19) | (0.44) | (1.05) | (1.33) | |
Cash per Share |
5.24 | 5.34 | 5.68 | 7.19 | |
Shareholders Equity per Share |
3.32 | 3.49 | 3.27 | 3.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.32 | 3.49 | 3.27 | 3.71 | |
Free Cash Flow |
(42.08) | (95.09) | (226.22) | (264.18) | |
Working Capital |
1,109.93 | 1,195.18 | 1,252.17 | 1,325.33 | |
Capital Expenditures |
(5.62) | (6.26) | (3.48) | (16.59) | |
Net Current Asset Value |
206.67 | 288.85 | 242.16 | 268.63 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
162.26 | 135.18 | 113.15 | 96.43 | |
Average Payables |
492.19 | 366.97 | 292.61 | 370.63 | |
Average Inventory |
142.46 | 124.99 | 116.81 | 115.32 | |
Average Assets |
2,293.40 | 2,291.21 | 1,939.30 | 2,144.89 | |
Average Common Equity |
835.89 | 1,003.61 | 402.01 | 512.18 |
Columns are period end dates · fundamentals updated 2 Nov 2026